Table 1.

Application of MSCs-based therapy for ICH in humans

ID	Study type			Enrollment	Follow-up	Cell administration				Result (function/side-effect)	References
	Phase	Design	Allocation			Source	Dose	Route	Timing
NA	I/II	Open label	Nonrandomized	N = 2	6 months	BMSCs	5–6 × 107	IV	3 months–1 year	Improved/none	[57]
NA	I/II	Single-blind	Randomized	N = 4	2 years	HUMSCs	1–2.3 × 107	IV	6 months–20 years	Improved/none	[58]
NA	I/II	Single-blind	Nonrandomized	N = 60	6 months	BMSCs	1.4 × 106	IC	5–7 days	Improved/fever (5.3%)	[59]
NA	NA	NA	NA	N = 2	1 year	BMSCs	20 × 106 cells	ICV	≥ 6 months	Improved/none	[111]
NA	I/II	Single-blind	Nonrandomized	N = 110	1 year	BMSCs	(6.9–12.8) × 107	IT	3.01–6.89 days after surgery	Improved/fever (6.4%)	[62]
NA	I/II	Double-blind	Randomized	N = 5	5 years	BMSCs	8.5 × 105/kg	IV	> 1 year	Improved/none	[60]
NCT02274428	I	Open label	Nonrandomized	N = 9	2 months	HUMSCs	0.5–1 × 107	ICV	≤ 1 week	NA/none	[61]
NCT02283879	I	Open label	Randomized	N = 20	1 year	HUMSCs	2 × 107	IV	3 months–5 years	Active, not recruiting	NA
NCT03371329	I	Open label	Nonrandomized	N = 12	1 year	BMSCs	(0.5/1/2) × 106/kg	IV/ITV	≤ 3 days	Completed	NA
NCT02795052	I	Open label	Nonrandomized	N = 500	1 year	BMSCs	Unrevealed	IV/IN	≥ 6 months	Recruiting	NA
NCT01714167	I	Open label	Nonrandomized	N = 30	1 year	BMSCs	2–4 × 106	IC	3 months–5 years	Recruiting	NA
NCT01389453	II	Open label	Nonrandomized	N = 0	1 year	HUMSCs	Unrevealed	IV	10–21 days	Withdrawn	NA
NCT04074408	II	Single-blind	Randomized	N = 100	1 year	HUMSCs	Unrevealed	ITC	1 day after surgery	Recruiting	NA

IC intracerebral, ICV intracerebroventricular injection, IN intranasal, injection, IT intrathecal, ITV intraventricular, ITC intracavitary, IV intravenous, BMSCs bone-marrow derived mesenchymal stem cells, HUMSCs human umbilical cord mesenchymal stem cells, NA not applicable